Array BioPharma To Team With Merck

Array BioPharma said Monday it has entered into a clinical trial collaboration with Merck (MRK) to investigate the safety and efficacy of Array’s MEK inhibitor, binimetinib, with Merck’s anti-PD-1 therapy keytruda in metastatic colorectal cancer patients with mircosatellite stable tumors (MSS-CRC).

Preclinical and clinical evidence indicates that keytruda can be enhanced when used with a MEK inhibitor like binimetinib. Under the terms, Array and Merck will collaborate on a clinical trial to investigate the safety and efficacy of the combination of binimetinib with keytruda in MSS CRC patients. The study is expected to begin in the second half of 2017, and results from this first study will be used to determine optimal approaches to further clinical development of these combinations.

By Stephen Holmes